Immune Defense Protein Impact On Respiratory Immune Outcomes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorQuantec Ltd
About this trial
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
Eligibility criteria
Qualifiers
Age 60 years and older
Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
Able to read and understand English.
Able to read, understand, and provide informed consent.
Disqualifiers
Do not have a personal smartphone, internet access, or unwilling to download Chloe.
HIV/AIDS
Chronic hepatitis B or C (advanced stages)
Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
Trial design
Treatments tested in this trial
- Immune Defense Protein 50mg Dose
- IDP 200mg Dose
- Matching Placebo
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
Quantec Ltd
Lead sponsor
People Science, Inc.
Collaborator
Source ClinicalTrials.gov